Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Authors: C.J. Thieme et al.

Link to paper: https://www.medrxiv.org/content/10.1101/2020.05.13.20100636v1.full.pdf

Journal/ Pre-Print: medRxiv

Tags: Immunology/Immunity

Research Highlights

1. In COVID19 patients, T cells react to peptides from the SARS-CoV-2 Spike, Matrix and and Nucleocapsid proteins.

2. Higher percentage of CD4+ than CD8+ T cells are reactive to SARS-CoV-2 with both harboring different recognition-patterns.

Summary 

The authors assess the SARS-CoV-2 directed T cell responses in moderate, severe and critical COVID-19 patients. To this end, they used overlapping peptide pools from SARS-Cov2 Spike (S), Matrix (M) and Nucleocapsid (N) proteins to stimulate PBMCs from COVID-19 patients. They find a significant frequency of M and N-reactive T cell responses in parallel to the well-studied S protein. The study highlights the relevance of focusing not only on S, but also on M and N protein for intervention strategies. Critical COVID-19 patients have similar percentages of SARS-CoV-2 S-, M-, and N-protein reactive CD4 and CD8 T cells as those of mild COVID19 patients. CD4+ T cell reactive responses were greater in terms of percentage of patients and range of targets than CD8 T cell responses. However, reactive CD8 T cells harboured effector/memory phenotypes that suggest either a pre-existing immunity or an earlier CD8+ T cell activation.

Impact for SARS-CoV2/COVID19 research efforts

Understand the immune response to SARS-CoV2/COVID19

Study Type

· In vitro study using patient samples

Strengths and limitations of the paper

Novelty: The authors looked at T cell responses against peptide pools not only from S but also M and N SARS-CoV-2 protein in moderate, severe and critical COVID19 patients in the same study.

Standing in the field: Recently other studies assessed the target landscape of T-cell responses to SARS-Cov2 infected patients:

- In moderate and healthy donors using “megapools” of peptides well designed: https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3

- In moderate to severe patients: https://www.medrxiv.org/content/10.1101/2020.04.11.20062349v1

Appropriate statistics:

- small sample size (28 in total)

- appropriate statistics in terms of statistical correction applied

Viral model used: Peptide pools obtained from Miltenyi

Translatability: Study emphasises importance of analysing adaptive immune responses (humoral and cellular) against M and N proteins as focussing only on the S protein may be too reductive.

Main limitations:

- Study design not clear, they used multiple samples per patients which they allocated to different stimulation conditions (not every patient seems allocated in the 3 conditions)

- Authors should show absolute numbers instead of percentages of reactive T cells in the comparison with disease severity, as lymphopenia is observed in critical COVID19 patients.

- Did not show the percentage of the positive cells in FACS gates for the gating strategy

- Peptide pools are not as complete as in other studies (https://www.cell.com/cell/fulltext/S0092-8674(20)30610-3)

- It would have been informative to assess reactivity across the different stimulation conditions for each patient.

- Did not study differential responses during the progression of the disease (e.g. at time of hospitalisation and after recovery).